Translational Lung Cancer Research

Article	Citations
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report	79
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors	70
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer	54
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series	47
Pushing the boundaries of minimally invasive surgery	46
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer	36
Density and maturity ratio of tertiary lymphoid structures in stage II–III non-small cell lung cancer predict postoperative recurrence risk	33
End-to-side anastomosis in complex tracheal resection and reconstruction: a case series study	32
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network	31
Real-time digital polymerase chain reaction (PCR) as a novel technology improves limit of detection for rare allele assays	30
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)	29
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review	29
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report	27
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer	27
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–2030	26
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma	25
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer	25
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression	25
Real-world data on severe lung cancer: a multicenter retrospective study	25
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?	24
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?	24
Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study	23
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety	23
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer	23
Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell	23

Development of an AI model for predicting hypoxia status and prognosis in non-small cell lung cancer using multi-modal data	23
Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor	22
Hyperthermic intrathoracic chemotherapy in overcoming tyrosine kinase inhibitor resistance in a patient with malignant pleural effusion: a case report	22
Discrepancies in PD-L1 expression, lymphocyte infiltration, and tumor mutational burden in non-small cell lung cancer and matched brain metastases	22
Needle tract seeding after endobronchial ultrasound-guided intranodal forceps biopsy and cryobiopsy: a case report	22
Comparative survival outcomes between EGFR-wildtype and EGFR-mutant lung adenocarcinoma following neoadjuvant chemoimmunotherapy: a retrospective cohort study from national cancer center in China	21
DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy	21
Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study	21
PD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma	21
Survival outcomes and risk factors after lung transplantation in patients with pre-transplant malignancy: a national cohort study	20
Sacituzumab govitecan: a new hope for patients with pretreated extensive small-cell lung cancer (SCLC)—insights from the TROPiCS-03 trial	20
Dynamic change of CD8+ T cell: immunotherapy fate tell?	20
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA	20
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer	20
Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study	19
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration	19
Advancements of ALK inhibition of non-small cell lung cancer: a literature review	19
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer	19
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with con	19
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?	18
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions	18
Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) da	18
Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study	18
Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial	18
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer	18
Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study	18
Treatment patterns and clinical outcomes of resectable central non-small cell lung cancer patients undergoing sleeve lobectomy: a large-scale, single-center, real-world study	18
Tackling a caveat of the FLAURA trial and building solid evidence for frail patients in thoracic oncology	18
Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database	18
Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients	17
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18	17
Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort	17
Follow-up regimen after lung cancer treatment: about the how and why	17
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer—thoughts from the KEYNOTE-671 trial	17
Circulating tumor cell methylation profiles reveal the classification and evolution of non-small cell lung cancer	17
Exploration of a novel prognostic model based on nomogram in non-small cell lung cancer patients with distant organ metastasis: implications for immunotherapy	17
How SOLID is the immune system’s response to the deadly duo of lung cancer and SARS-CoV-2?	17
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic	17
The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer	17
The long-term oncologic outcomes of robot-assisted bronchial single sleeve lobectomy for 104 consecutive patients with centrally located non-small cell lung cancer	16
Another point of view for meta-analysis studies focused on protective inhaled corticosteroids and the risk of lung cancer	16
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions	16
Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients	16
Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study	16
Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival?	16
Evaluating three-dimensional lung reconstructions for thoracoscopic lung resections using open-source software: a pilot study	16
Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases	15
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged N	15
Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50%	15
Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications	15

Spontaneous ventilation video-assisted thoracoscopic surgery for octogenarian non-small cell lung cancer patients: a non-inferiority study	15
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review	15
A case series of nonintubated robotic-assisted bronchoscopy: a feasible alternative to intubated techniques	15
Single-cell and spatial transcriptomics reveal a potential role of ATF3 in brain metastasis of lung adenocarcinoma	14
Preclinical evaluation of thin convex probe endobronchial ultrasound-guided transbronchial needle aspiration for intrapulmonary lesions	14
One-year mortality risk prediction model for patients with interstitial lung disease and lung cancer	14
International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer	14
Will “Sun”-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?	14
Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through SPRED1	14
Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer	14
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review	14
DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges	14
Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study	14
LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma	14
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer	13
Are polygenic risk scores ready for the cancer clinic?—a perspective	13
PD-1 expression on tumor cells: a new target for cancer therapy	13
Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC	13
Use of tumor cell lysate to develop peptide vaccine targeting cancer-testis antigens	13
Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report	13
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study	13
Patient-reported impact of symptoms in lung cancer (PRISM-LC)	13
Cancer cachexia research: coming of age	13
Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer	12
SMARCA4 deficiency: implications for non-small cell lung cancer and management strategies, with relevance to and distinctions from thoracic undifferentiated tumor	12
Paving the way for ctDNA-guided trials in lung cancer: insights from the LIBELULE study	12
Association of cholesterol and triglyceride levels with the recurrence of early-stage lung adenocarcinoma with micropapillary pattern	12
Future lung cancer prediction using low-dose chest computed tomography	12
Dual immuno-oncology agents as neoadjuvant therapy for patients with resectable non-small cell lung cancer	12
Enhancing the precision of auxiliary diagnosis for lung cancer through use of SHOX2 and RASSF1A methylation status in lung biopsy and lymph node biopsy specimens	12
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study	12
Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion	12
Editorial on: are we achieving ultimative limits of the minimally invasive thoracic surgery?	12
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic	12
Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow	12
Role of radiomics in predicting lung cancer spread through air spaces in a heterogeneous dataset	12
Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy	11
Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patie	11
Outcomes and prognostic insights in primary tracheal cancer: a multicenter retrospective study	11
Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally ad	11
Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer	11
Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China	11
Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review	11
Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors	11
A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced	11
Predictive value of the monocyte-to-high-density lipoprotein ratio in the prognosis of non-small cell lung cancer patients after surgery	11
Integrating deep learning and radiomics in the differentiation of major histological subtypes of invasive non-mucinous lung adenocarcinoma using positron emission tomography and computed tomography	11
Exploring the efficacy of artificial neural networks in predicting lung cancer recurrence: a retrospective study based on patient records	11
Lung cancer susceptibility beyond smoking history: opportunities and challenges	11
Metabolite biomarkers in lung cancer: unlocking the potential of body fluid analysis for early detection and prognosis—a narrative review	10
The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study	10
Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”	10
Cellular senescence and lung cancer prognosis	10
Utility of ctDNA-molecular residual disease in predicting minimal residual disease in non-small cell lung cancer patients after radical resection	10
Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer	10
The OPEN trial—from the darkness, comes light	10
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers	10
Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study	10
Radiomic phenotypes of oligometastatic non-small cell lung cancer	10
Natural course of lung adenocarcinoma manifesting as ground-glass nodules: invasiveness assessment based on growth evaluation	10
Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?	10
Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer	10
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer	10
Reducing radiation pneumonitis in lung cancer patients: from Chinese expert consensus to practice	10
Age at first sexual intercourse, age at menarche, and age at menopause: a mendelian randomization study on lung cancer risk	10
Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations	10
Good responses to first-line immunotherapy-included treatment in lung squamous carcinoma with rare driver gene mutations: a report of three cases	10
Learning curve for uniportal thoracoscopic pulmonary segmentectomy: how many procedures are required to acquire expertise?	10
What do we know about the role of neoadjuvant targeted therapy in early-stage EGFR-mutant and ALK-fused non-small cell lung cancer?—a narrative review of the current literature	10
From tradition to transformation: evolving paradigms in surgical lung cancer treatment	10
Lymph node dissection of station 8 improves the survival of T≤3 cmN0M0 lung adenocarcinoma patients	10
Altered carnitine transporter genes (SLC22A5, SLC22A16, SLC6A14) expression pattern among lung cancer patients	10
False positivity in break apart fluorescence in-situ hybridization due to polyploidy	10
Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach	10
A prediction model integrated genomic alterations and immune signatures of tumor immune microenvironment for early recurrence of stage I NSCLC after curative resection	10
Biomarkers as a tool to reduce disparities in lung cancer screening and detection	9
Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review	9
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma	9
Comparative efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy versus combined EGFR-TKI and chemotherapy in resectable EGFR-mutant non-small cell lung cancer	9
Integrating radiomics and deep learning for enhanced prediction of high-grade patterns in stage IA lung adenocarcinoma	9

A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab	9
The APPLE trial in the evolving landscape of ctDNA monitoring	9
A multiethnic bidirectional Mendelian randomization study negates causal effects of C-reactive protein concentrations on lung cancer	9
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review	9
Racial disparities in histological subtype, stage, tumor grade and cancer-specific survival in lung cancer	9
Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients	9
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review	9
Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression	9
Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study	9
Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report	9
Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer	9
Fibre-based fluorescence-lifetime imaging microscopy: a real-time biopsy guidance tool for suspected lung cancer	9
Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence	9
Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC)	9
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer	8
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study	8
Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer	8
Safety and efficacy of transbronchial radiofrequency ablation for stage IA peripheral lung cancer: a retrospective cohort study	8
Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with MET-altered non-small-cell lung cancer: a narrative review	8
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)	8
Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer	8
Prognostic implications of MDM2 expression in surgically resected epidermal growth factor receptor mutant lung cancer with pathological lymph node metastasis	8
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study	8
STING facilitates the development of radiation-induced lung injury via regulating the PERK/eIF2α pathway	8
Residual tumor descriptors proposed by the International Association for the Study of Lung Cancer may not be applicable to stage I and ground-glass opacity-featured non-small cell lung cancer	8
Pneumonectomy—a necessary evil?	8
BRAF RNA is prognostic and widely expressed in lung adenocarcinoma	8
Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance	8
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma	8
Extending the clinical indications of liquid biopsy: plasma next-generation sequencing in suspected lung cancer	8
Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations	8
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22	8
Integrative genomic profiling reveals characteristics of lymph node metastasis in small cell lung cancer	8
Multidisciplinary international expert consensus on perioperative airway management	8
Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer	8
Invasive mucinous adenocarcinoma harbored MET exon 14 skipping mutation: case report	8
DeepGR: a deep-learning prognostic model based on glycolytic radiomics for non-small cell lung cancer	8
The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential b	7
Augmented reality navigation-guided intraoperative pulmonary nodule localization: a pilot study	7
Fuel for thought: targeting metabolism in lung cancer	7
Influencing factors and prediction of growth heterogeneity in solid nodule non-small cell lung cancer based on artificial intelligence: a prospective study	7
EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population	7
A narrative review of immunotherapy for non-small cell lung cancer: current progress, sensitization approaches, and synergistic strategies	7
Improved diagnostic accuracy with three lung tumor markers compared to six-marker panel	7
Contribution of crosstalk of mesothelial and tumoral epithelial cells in pleural metastasis of lung cancer	7
PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysis	7
Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis	7
Investigation of non-completion factors for durvalumab maintenance therapy in locally advanced non-small cell lung cancer	7
Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB)	7
Predicting survival in small cell lung cancer patients undergoing various treatments: a machine learning approach	7
Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study	7
Construction and validation of a novel ferroptosis-related prognostic signature for lung adenocarcinoma	7
Endoplasmic reticulum stress-related genes contribute to lung cancer risk: a multiomics data integration study	7
Recurrence prediction of lung adenocarcinoma using an immune gene expression and clinical data trained and validated support vector machine classifier	7
Deep learning model for predicting spread through air spaces of lung adenocarcinoma based on transfer learning mechanism	7
Construction of a neutrophil extracellular trap formation-related gene model for predicting the survival of lung adenocarcinoma patients and their response to immunotherapy	7
Impact of lymph node dissection on cancer-specific survival in non-small cell lung cancer patients: a SEER database analysis	7
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated n	7
Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review	7
Aurora kinase B inhibition in small-cell lung cancer: BCL-2 as a potential therapeutic biomarker and combination target	7
The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy	7
Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives	7
Towards the development of next-generation lung cancer immunotherapy	7
The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases	7
Prognostic value of L4 lymph node dissection during video-assisted thoracoscopic surgery in patients with left-sided non-small cell lung cancer: a single-center, retrospective cohort study	7
Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report	7
Local consolidative therapy for the primary tumor in EGFR-mutant advanced non-small cell lung cancer following osimertinib plus chemotherapy: a protocol for a single-arm, open-label, phase 2 trial	7
EGFR inhibitors plus dabrafenib and trametinib in patients with EGFR-mutant lung cancer and resistance mediated by BRAFV600E mutation: a multi-center real-world experience in China	6
A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer	6
A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome	6
Development of a cuproptosis-related signature for prognosis prediction in lung adenocarcinoma based on WGCNA	6
The strategy of non-intubated spontaneous ventilation anesthesia for upper tracheal surgery: a retrospective case series study	6
Comparative study of bronchoscopic and CT-guided percutaneous microwave ablation for inoperable non-small cell lung cancer	6
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study	6
Patient-focused insights: how emotional distress shapes immunotherapy response in non-small cell lung cancer	6
Genomic alterations dissection revealed MUC4 mutation as a potential driver in lung adenocarcinoma local recurrence	6
Clinical application of three-dimensional reconstruction in anatomical analysis of the right anterior, lateral, and posterior basal segments (RS8, RS9, and RS10) for RS9 segmentectomy	6
Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report	6
Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospectiv	6
Comparative characteristics of small cell lung cancer and Ewing’s sarcoma: a narrative review	6
Shift in lung cancer stage at diagnosis during the COVID-19 pandemic in New York City	6
MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer	6
NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma	6
Incremental prognostic value of solid component volume ratio and entropy for pathological stage IA invasive lung adenocarcinoma after surgery	6
Association of systemic therapy with survival among adults with advanced non-small cell lung cancer	6
TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemorad	6
Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer	6
Decoding the tumor immune microenvironment in lung squamous cell carcinoma: characteristics, regulatory mechanisms, and future directions in immunotherapy	6
Surgical series in mesothelioma: navigating between biases	6
International expert consensus on immunotherapy for early-stage non-small cell lung cancer	6
Erratum to EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates	6
Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study	6
Ion robotic bronchoscopy laser ablation and Da Vinci robotic segmentectomy for bilateral pulmonary nodules: a case report	6
Review of the use of radiomics to assess the risk of recurrence in early-stage non-small cell lung cancer	6
KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component	6